HCP and patient engagement
Closed-Loop Marketing Systems for Pharma HCP Field Teams
Pharma field teams waste $20 billion annually on content reps never use.
Marcus Thibodeau
Contributing Editor · · 12 min read
The Promo Review
The Latest
Modular content and claims management
Claims Substantiation Standards for Comparative Efficacy Statements
Comparative claims require direct testing against current competitors, not marketing intuition.
Renata Solis-Vega
Modular content and claims management
AI-Assisted Claims Tagging in Promotional Content Libraries
Regulators now penalize unsubstantiated AI marketing claims with rising enforcement and fines.
Priya Nambiar
Modular content and claims management
Core Claims Matrix Development for New Drug Approvals
Structured claims mapping helps pharma avoid regulatory trouble at launch.
Priya Nambiar
Modular content and claims management
Global Modular Content Frameworks in Multinational Drug Launches
Modular content frameworks cut drug launch delays by pre-approving reusable pieces.
Marcus Thibodeau
MLR and promotional review
Handling Unsolicited Requests for Off-Label Drug Information
Manufacturers must verify requests are unsolicited before sharing off-label drug information.
Renata Solis-Vega
MLR and promotional review
Social Media Promotional Content Under FDA Off-Label Oversight
FDA targets off-label drug promotion on social media after a decade of regulatory neglect.
David Osei-Bonsu
MLR and promotional review
Veeva Vault PromoMats Configuration for MLR Cycle Management
Configuration choices in lifecycle, workflow, and roles determine if MLR review takes days or weeks.
Marcus Thibodeau
MLR and promotional review
FDA Draft Guidance on Directional Risk Information in Promotional Labeling
Sixteen-year-old draft rules now guide how FDA polices drug risk disclosures.
Priya Nambiar
MLR and promotional review
MLR Review Metrics That Signal Process Breakdown
FDA enforcement letters in 2025 signal urgent need to catch MLR process failures early.
Renata Solis-Vega
MLR and promotional review
Annotated Promotional Piece Requirements for MLR Submissions
Every claim in a drug ad must trace back to documented sources before FDA review.
Priya Nambiar